These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31200953)

  • 1. ILCs in hematologic malignancies: Tumor cell killers and tissue healers.
    Blom B; van Hoeven V; Hazenberg MD
    Semin Immunol; 2019 Feb; 41():101279. PubMed ID: 31200953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
    Zaghi E; Calvi M; Di Vito C; Mavilio D
    Front Immunol; 2019; 10():2794. PubMed ID: 31849972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
    Xiong Y; Bensoussan D; Decot V
    Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Essential Role of Innate Lymphoid Cells in the Pathophysiology of Graft-vs.-Host Disease.
    Shao L; Pan S; Zhang QP; Jamal M; Chen LH; Yin Q; Wu YJ; Xiong J; Xiao RJ; Kwong YL; Zhou FL; Lie AKW
    Front Immunol; 2019; 10():1233. PubMed ID: 31244831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells in malignant hematology: A primer for the non-immunologist.
    Kannan GS; Aquino-Lopez A; Lee DA
    Blood Rev; 2017 Mar; 31(2):1-10. PubMed ID: 27665023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
    Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
    Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate lymphoid cells in graft-versus-host disease.
    Konya V; Mjösberg J
    Am J Transplant; 2015 Nov; 15(11):2795-801. PubMed ID: 26228632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease.
    Munneke JM; Björklund AT; Mjösberg JM; Garming-Legert K; Bernink JH; Blom B; Huisman C; van Oers MH; Spits H; Malmberg KJ; Hazenberg MD
    Blood; 2014 Jul; 124(5):812-21. PubMed ID: 24855210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
    Tsirigotis P; Shimoni A; Nagler A
    Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoid reconstruction and vaccines.
    Gress RE; Komanduri KV; Einsele H; Cooper LJ
    Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):17-22. PubMed ID: 17222765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.
    Cruz CR; Bollard CM
    Haematologica; 2015 Jun; 100(6):709-19. PubMed ID: 26034113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy in hematopoietic stem cell transplantation.
    Kazemi MH; Kuhestani Dehaghi B; Roshandel E; Parkhideh S; Mehdizadeh M; Salimi M; Hajifathali A; Hamidpour M
    Hum Immunol; 2021 Sep; 82(9):640-648. PubMed ID: 34119352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
    Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
    Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
    Lin C; Horwitz ME; Rein LAM
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective and pathogenic functions of innate lymphoid cells in transplantation.
    Mak ML; Reid KT; Crome SQ
    Clin Exp Immunol; 2023 Jul; 213(1):23-39. PubMed ID: 37119279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
    Liu J; Zhong JF; Zhang X; Zhang C
    J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
    Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
    Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
    Locatelli F; Merli P; Rutella S
    J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?
    Shimoni A; Nagler A
    Leuk Lymphoma; 2009 Sep; 50(9):1395-6. PubMed ID: 19672777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.